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Abstract
Background Microvascular decompression (MVD) and par-
tial sensory rhizotomy (PSR) provide longstanding pain relief
in trigeminal neuralgia (TN). Given their invasiveness, com-
plications can result from such posterior fossa procedures, but
the impact of these procedures and their complications on
patient-reported outcome measures (PROM), such as quality
of life and distress, are not well established.
Method Five years after surgery, patients who underwent first
MVD or PSR for TN at one institution, between 1982 and
2002, were sent a self-completion assessment set containing
a range of PROMs: the Short Form-12 (SF-12) questionnaire
to assess quality of life, the Hospital Anxiety and Depression
Scale (HADS) to assess distress, and a questionnaire contain-
ing questions about postoperative complications, their severi-
ty and impact on quality of life. These findings and demo-
graphic data were compared between MVD and PSR.
Results One hundred and eighty-one of 245 (73.9%) pa-
tients after first MVD and 49 of 60 (81.7%) after PSR
responded, and were included in analyses. The mean SF-
12 scores of patients after MVD and PSR at five-year
follow-up were significantly lower than English age-
matched norms. Though there were no differences in
SF-12 physical or mental component scores between the
two procedures, patients after PSR were more likely to
have case-level anxiety (RR = 3.3; 95% CI, 1.1–10.5;
p = 0.03), had more postoperative complications, and of
greater severity, including pain (RR = 2.52; 95% CI, 1.5–
4.1; p < 0.001), numbness (RR = 5.9; 95% CI, 3.8–9.2;
p < 0.001), burning sensations (RR = 3.0; 95% CI, 1.5–
5.8; p = 0.001) and difficulty in eating (RR = 17.1; 95%
CI, 5.6–53.1; p < 0.001), and these had a larger impact on
quality of life for PSR compared to MVD.
Conclusions The quality of life 5 years after MVD or PSR is
poorer than in the general population and associated with
postoperative complications such as pain, numbness, burning
sensation and difficulty in eating. These complications are
commoner after PSR than MVD, and this is associated with
anxiety in PSR patients at five-year follow-up. However, these
differences are not reflected by quality of life scores. Outcome
measures need to incorporate patient experience after treat-
ment for TN, and represent patient priorities for quality of life.
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Trigeminal neuralgia (TN) presents with severe, unilateral,
electric shock-like facial pain provoked by light touch,
resulting in significant social disability and associated anxiety
and depression [1, 2]. Treatment with anticonvulsant drugs
provides some patients with prolonged pain relief and accept-
able quality of life. For other patients, the variety of surgical
techniques available for TN provide the longest period of pain
relief, with a low but significant morbidity and mortality
[3–5]. These include invasive posterior fossa procedures, such
as microvascular decompression (MVD), partial sensory rhi-
zotomy (PSR), or more recently, internal neurolysis. If
neurovascular compression (NVC) is found on magnetic res-
onance imaging (MRI), MVD is performed, with the aim of
decompressing the trigeminal nerve in the region of the root
entry zone, where pressure from major arterial vessels is most
likely to occur. PSR or internal neurolysis are only carried out
if no NVC is found. PSR entails the division of the lateral part
of the sensory root, whereas internal neurolysis entails sepa-
rating nerve fibres longitudinally, and it is postulated that the
latter causes less injury to the nerve. PSR, therefore, has be-
come less common [4].
Despite the range of surgical techniques on offer for TN,
there are few randomised controlled trials of their efficacy, and
existing cohort studies are usually retrospective and of poor
quality [6]. These studies do not use standardised outcome
measures, making results hard to interpret and compare,
resulting in difficulty for patients in choosing between surgical
techniques [7, 8]. The primary outcome measure used inmany
surgical studies for TN is pain relief with or without medica-
tion, with neglect of patient-reported outcome measures
(PROMs) such as quality of life. Use of PROMS may high-
light the potential benefits of posterior fossa procedures for
TN over medical management [6]. PROMs to measure pain
and its impact have been used in TN, but the impact of other
factors on quality of life, such as the fear of return of pain after
MVD, or the incidence of numbness after destructive proce-
dures like PSR, is unexplored [9, 10]. A systematic assess-
ment and comparison of the effect of these postoperative com-
plications on quality of life is needed.
Aims and hypothesis
In this cross-sectional study, we aimed to establish long-term
PROMs after first MVD or PSR for TN, including quality of
life and distress. Since PSR results in a higher incidence of
postoperative complications, while pain relief fromMVD and
PSR is equivalent [10], we expected to find poorer quality of
life and distress in patients undergoing PSR than in patients
undergoing their first MVD. We also aimed to determine the
relative impact of common postoperative complications on
PROMs, 5 years after MVD or PSR.
Methods
This cross-sectional study is reported in accordance with the
STROBE checklist for observational studies [11]. Ethical ap-
proval was given by Frenchay Hospital Bristol LREC (Project
Number 2001/60).
Participants and eligibility
Patients were drawn from one neurosurgeon’s entire posterior
fossa surgery practice from 1982 to 2002, previously reported
in terms of pain recurrence and satisfactionwith outcome [12].
The inclusion criteria were: patients with primary idiopathic
TN using the diagnostic criteria of International Classification
for Headache Disorders [13], and patients who had been
followed-up prospectively after MVD or PSR with an opera-
tion 6months or longer before the survey had been carried out.
The exclusion criteria were: patients with a secondary cause of
TN, clinical evidence of multiple sclerosis, concurrent cranial
nerve disorder such as hemifacial spasm, or significant co-
morbidities that might influence quality of life or distress.
Data collection
Patients were posted a self-completion assessment set relating
to PROMs [14]. The Medical Outcomes Study Short Form-12
questionnaire (SF-12) and the Hospital Anxiety and
Depression Scale (HADS) were included in the set. Included
were questions about the most common postoperative compli-
cations, including their presence, severity and impact on qual-
ity of life reported by the patient (Fig. 1). Completed assess-
ments were returned to independent observers, including one
physician, one neurosurgeon and a patient from the
Trigeminal Neuralgia Association UK. For patients who
responded, electronic healthcare records were used to provide
demographic data including age, gender, co-morbidities, pre-
vious surgery, mean duration of symptoms, side of pain, divi-
sion(s) of the trigeminal nerve affected and current use of
medication. The clinical outcomes for this population have
already been reported [12]. The main outcome measures for
both MVD and PSR patients were PROMs, including: ques-
tionnaire results for postoperative complications, quality of
life and distress.
The Short-Form 36 (SF-36) and its shorter version, the SF-
12, are broad health survey questionnaires used in large stud-
ies to assess quality of life across a range of mental and phys-
ical health conditions [15]. The SF-12 consists of 12 questions
Acta Neurochir
in eight domains: physical functioning, role physical, bodily
pain, general health, vitality, social functioning, role emotional
and mental health. A raw score for each of the eight domains is
calculated, and these scores are weighted and transformed into
SF-12 Physical Component Scores (PCS) and Mental
Component Scores (MCS), corresponding to the physical and
mental dimensions of quality of life, and scored from 0 to 100,
where 0 is the lowest possible quality of life, 100 is the highest
possible quality of life, and 50 represents the 1998 United States
population average. SF-12 scores were calculated as standard
[16]. For analyses, SF-12 scores for the MVD and PSR groups
were compared with normative data from English 50– to 64-
year-olds, collected in 2012 [17]. The HADS is designed for
assessment of distress in patients with medical problems, and
has been used to evaluate effects of surgery for TN [10, 14,
18]. It is a 14-item scale, with seven items corresponding to
anxiety and seven to depression. The response to each item is
scored from 0 (absence of symptom) to 3 (high level of symp-
tom), giving scores of 0–21 for anxiety and depression. The cut
of point of 8/21 is used for borderline anxiety or depression, and
11/21 for case-level anxiety or depression [19]. The HADS anx-
iety and HADS depression scores for each patient were then
dichotomised either to borderline anxiety and depression or
not, and case-level anxiety or depression or not.
Data analysis
Scores for the SF-12 PCS and MCS were compared for MVD
and PSR groups using Mann-Whitney U tests. For the HADS,
MVD and PSR groups were compared for the numbers of pa-
tients with borderline levels or case levels of anxiety or depres-
sion using χ2 tests. Where demographic factors were significant-
ly different between groups, their effect on the SF-12 and HADS
within each group was determined using Mann-Whitney U tests
and χ2 or Fisher’s exact tests respectively. The numbers of pa-
tients with postoperative complications, and their severity and
impact on quality of life, were compared using χ2 tests.
Patients with surgery prior to MVD were separated from the
cohort and their results reported separately.
All data were managed using Microsoft Excel 2016
(Microsoft, Redmond, VA, USA). Statistical analyses were per-
formed using IBM SPSS Statistics for Macintosh, Version 24.0
(IBM, Armond, NY, USA). Mean values are reported with 95%
confidence intervals (95% CI), and median values are reported
with interquartile ranges (IQRs). For all statistics, p values less
than or equal to 0.05 were considered statistically significant.
Graphs were drawn using Prism for Macintosh, Version 7
(GraphPad Software, San Diego, CA, USA).
Results
Study participants
A mean of 5 years after their surgery, 305 patients, of whom
245 underwent MVD and 60 underwent PSR, were contacted
and posted self-completion assessment sets (Fig. 2), of whom
271 returned them. Two patients who underwent a PSR expe-
rienced bilateral facial pain, and were excluded as the side of
pain referred to in the PROMs was unknown. This left 269
(88.2%) from the original cohort. Thirty-nine of 220 (17.7%)
responders with an MVD had previous Gasserian ganglion sur-
gery; these were separated from the cohort, leaving 181 patients
after MVD (59.2%) and 49 patients after PSR (81.7%) for main
analyses.
The characteristics of the 194 patients are described in
Table 1. Some variables had missing data in either or both
groups, indicated by the smaller denominators. There was a
significant difference between the division of the trigeminal
nerve affected between MVD and PSR groups (χ2 = 23.7;
p = 0.001). There was also a higher proportion of medication
use (χ2 = 8.52; p = 0.004) in patients who underwent a PSR
compared to MVD. Patient co-morbidities were separated into
those which were unlikely to have an impact upon quality of
Fig. 1 Self-assessment questionnaire. Questions and possible answers
provided by the questionnaire as part of the self-assessment set.
Severity and impact upon quality of life was asked separately for each
postoperative complication. *Possible responses for severity of burning
sensation or difficulty in eating differed from severity of numbness, and
were: severe, quite a bit, moderate or a little bit
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life, and those that were, after consensus between a clinician
and a psychologist. Of those with co-morbidities, there was a
higher proportion of patients with co-morbidities that were like-
ly to impact quality of life after MVD (n = 38/73; 52.1%)
compared to PSR (n= 4/15; 26.7%), but this was not significant
(Fisher’s exact test; p = 0.092). Nineteen patients out of 49
(38.8%) had previous surgery before PSR. The characteristics
of patients with a previous surgery before MVD are reported in
Table 2.
PROMs after MVD or PSR
The SF-12 and HADS were used to compare patients 5 years
after MVD or PSR (Supplementary Material 1). There were
no significant differences between the median SF-12 physical
component score or median mental component score of pa-
tients in the two groups, but mean SF-12 scores for both were
significantly lower than contemporary English norms for 50–
to 64-year-olds (n = 2,214): mean PCS, 46.2 (SD, 11.8) and
Table 1 Patient characteristics
by group and differences between
groups
Patient characteristic MVD group (n = 181) PSR group
(n = 49)
Test, p value
Mean age in years (± SD) 59.3 (± 11.6) 56.9 (± 12.2) t = 1.24 n.s.
Gender: female (%) 108 (57.9) 34 (69.4) χ2 = 1.54 n.s.
Other co-morbidities (%) 78 (43.1) 16 (32.7) χ2 = 1.74 n.s.
Median duration of symptoms in years
(IQR)
5.0 (2.5–8.0) 4.0 (2.0–9.0) U = 2,802.0
n.s.






Division affected (%) χ2 = 23.7
p = 0.001
V1 11/164 (6.7) 0/46 (0.0)
V2 20/164 (12.2) 10/46 (21.7)
V3 36/164 (22.0) 10/46 (21.7)
V1 + V2 27/164 (16.5) 0/46 (0.0)
V2 + V3 13/164 (7.9) 1/46 (2.2)
V1 + V2 + V3 57/164 (34.8) 25/46 (54.3)
Currently taking medication for pain (%) 14/180 (7.8) 11/49 (22.4) χ2 = 8.52
p = 0.004
Occasional use 2/14 (14.2) 2/10 (20.0)
Once daily use 9/14 (64.3) 6/10 (60.0)
Use twice daily or more 3/14 (21.4) 2/10 (20.0)
Fig. 2 Participant flow diagram
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mean MCS 51.5 (SD, 9.9) (Fig. 3). ANOVA with Tukey’s
pairwise comparisons showed significantly lower PCS and
MCS scores after MVD (F = 33.6; p < 0.0001 for both PCS
and MCS) or PSR (F = 22.1; p < 0.0063 for PCS and
p = 0.0002 forMCS). Using χ2 tests, it was found that patients
after PSR were more likely to have case-level anxiety, scoring
11/21 on the HADS, than after MVD (relative risk; RR = 3.3;
95% CI, 1.1–10.5; χ2 = 4.71; p = 0.03).
Of 39 patients with previous surgery after MVD, 31 com-
pleted the SF-12. Their median SF-12 PCS was 39.2 (IQR,
36.2–44.3) and median SF-12 MCS was 45.0 (IQR, 41.3–
51.3). Thirty-eight of these patients completed the HADS, of
whom 14 (36.8%) demonstrated borderline anxiety on the
HADS, five (13.2%) case-level anxiety, nine (23.7%) border-
line depression and three (8.9%) case-level depression. To
determine the effect on PROMs of the differences in charac-
teristics between groups, division of the trigeminal nerve af-
fected and medication use were compared by PROMs within
the MVD and PSR groups using Mann-Whitney U tests and
contingency analyses. In the MVD group, patients on regular
pain medication were more likely to have borderline depres-
sion (Fisher’s exact test; p = 0.043), whereas in the PSR
group, medication use was also associated with case-level
depression (Fisher’s exact test; p = 0.008). Also in the PSR
group, the median SF-12 MCS of those on medication at
follow-up (median, 39.1; IQR, 28.6–49.7) was significantly
lower than that of those not taking medication (median, 49.4;
IQR, 42.8–50.9; U = 81.0; p = 0.02).
PROMs by postoperative complication afterMVD or PSR
The most common postoperative complications were pain,
numbness, burning sensations and difficulty in eating. A com-
parison of the two surgical procedures in terms of postopera-
tive complications was made (Table 3). Significantly greater
proportions of patients experienced pain (RR = 2.52; 95% CI,
1.5–4.1), numbness (RR = 5.9; 95% CI, 3.8–9.2), burning
Fig. 3 Comparison of SF-12 PCS and MCS with UK norms from 2012.
The mean SF-12 PCS (a) and MCS (b) scores of MVD and PSR patients
and those of English norms of 50– to 64-year-olds in 2012 were
compared using ANOVA and Tukey’s pairwise multiple comparisons.
Error bars represent standard deviations; significance levels: *
p < 0.05, ** p < 0.01
Table 2 Patient characteristics of MVD patients with previous surgery
Patient characteristic MVD group with
previous surgery (n = 39)
Mean age in years (± SD) 59.3 (± 11.6)
Gender: female (%) 23 (59.0)
Other co-morbidities (%) 19 (48.9)
Median duration of symptoms
in years (IQR)
5.0 (2.5–8.0)





V1 + V2 6/37 (16.2)
V2 + V3 2/37 (5.4)
V1 + V2 + V3 8/37 (21.6)
Currently taking medication for pain (%) 10 (25.6)
Occasional use 1/10 (10.0)
Once daily use 9/10 (90.0)
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Table 4 Impact of postoperative
complications on quality of life
between MVD and PSR




PSR group Test, p value
Impact of numbness on quality of life (%) χ2 = 81.1,
p < 0.001
Severe 0/20 (0.0) 2/36 (5.6)
Quite a bit 0/20 (0.0) 5/36 (13.9)
Moderately 2/20 (10.0) 7/36 (19.4)
A little bit 6/20 (30.0) 11/36
(30.6)




Impact of burning on quality of life (%) χ2 = 26.0,
p < 0.001
Severe 0/15 (0.0) 3/15 (20.0)
Quite a bit 0/15 (0.0) 2/15 (13.3)
Moderately 1/15 (6.7) 4/15 (26.7)
A little bit 5/15 (33.3) 4/15 (26.7)
Not at all 9/15 (60.0) 2/15 (13.3)
Impact of difficulty in eating on quality of life (%) χ2 = 39.5,
p < 0.001
Severe 0/7 (0.0) 3/17 (17.6)
Quite a bit 0/7 (0.0) 2/17 (11.8)
Moderately 0/7 (0.0) 2/17 (11.8)
A little bit 3/7 (42.9) 7/17 (41.2)
Not at all 4/7 (57.1) 3/17 (17.6)
Table 3 Postoperative
complications and severity after
MVD or PSR
Postoperative complication MVD group PSR group Test, p value
Pain (%) 25/157 (15.9) 18/42 (42.9) χ2 = 12.4, p < 0.001
Excruciating 2/25 (8.0) 1/18 (5.6)
Horrible 5/25 (20.0) 3/18 (16.7)
Distressing 7/25 (28.0) 2/18 (11.1)
Discomforting 5/25 (20.0) 10/18 (55.6)
Mild 6/25 (24.0) 2/18 (11.1)
Numbness (%) 20/157 (14.6) 6/48 (75.0) χ2 = 71.7, p < 0.001
Very severe 2/20 (10.0) 3/36 (8.3)
Severe 1/20 (5.0) 9/36 (25.0)
Moderate 5/20 (25.0) 10/36 (27.8)
Mild 5/20 (25.0) 8/36 (22.2)
Very mild 7/20 (35.0) 6/36 (16.7)
Burning (%) 14/157 (8.9) 13/49 (26.5) χ2 = 10.2, p = 0.0014
Severe 0/14 (0.0) 2/13 (15.4)
Quite a bit 2/14 (14.3) 5/13 (38.5)
Moderate 1/14 (7.1) 2/13 (15.4)
A little bit 11/14 (78.6) 4/13 (30.8)
Difficulty in eating (%) 3/157 (1.9) 16/49 (32.7) Fisher’s test, p < 0.001
Severe 0/3 (0.0) 3/16 (18.8)
Quite a bit 0/3 (0.0) 2/16 (12.5)
Moderate 1/3 (33.3) 5/16 (31.3)
A little bit 2/3 (66.7) 6/16 (37.5)
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sensation (RR = 3.0; 95% CI, 1.5–5.8) and difficulty in eating
(RR = 17.1; 95% CI, 5.6–53.1) after PSR than after MVD.
Patients directly rated the impact of each postoperative com-
plication on their quality of life (Fig. 1). For both MVD and
PSR, the severity rating for each postoperative complication
correlated with the rating of impact on quality of life
(p < 0.001). Data for the impact of pain on quality of life
was not available. PSR patients reported greater impact on
quality of life of numbness (χ2 = 81.1; p < 0.001), burning
(χ2 = 26.0; p < 0.001) and difficulty in eating (χ2 = 39.5;
p < 0.001) than MVD patients (Table 4). The presence of
postoperative complications, their severity and impact on
quality of life in patients who had surgery prior to their
MVD are reported in Table 5.
Discussion
This prospective study assessed all patients with TN a mean
5 years after MVD or PSR using a range of PROMs, including
SF-12, the HADS and questions about postoperative compli-
cations. The results varied according to the PROM used.
Patients’ responses supported our main hypothesis, that
PSR, given its higher rate and severity of complications
[12], is associated with poorer quality of life and that pain
recurrence is not the only factor impacting on quality of life.
The SF-12 showed that the physical and mental dimensions of
quality of life were lower in patients 5 years after posterior
fossa surgery than UK norms from 2012. The SF-12 did not
significantly differ between MVD and PSR, though patients
were over 3 times more likely to have case-level anxiety on
the HADS after PSR than after MVD.
This is the first study to prospectively compare long-term
PROMs between two posterior fossa procedures for the treat-
ment of TN. Survey and data collection were carried out by a
physician, neurosurgeon and patient, all of whom were inde-
pendent of the surgical unit. Patients with co-morbidities un-
related to facial pain were also included, ensuring the cohort
was as representative of the TN population as possible.
However, our study is not without limitations. As PSR is less
commonly performed than MVD, the number of patients in
the PSR group is relatively small, and so the comparison be-
tween the two procedures should be interpreted with caution.
Though the four most common postoperative complications
are reported in this cohort, this does not accommodate for
other complications, such as hearing loss, headaches, dizzi-
ness or visual problems, which may impact PROMs and ac-
count for the low SF-12 scores in both surgical groups [20,
Table 5 Postoperative
complications after MVD with
prior surgery
Postoperative complication Severity Impact on quality of life
Pain (%) 17/39 (43.6)
Excruciating 3/17 (17.6) –
Horrible 2/17 (11.8) –
Distressing 3/17 (17.6) –
Discomforting 5/17 (29.4) –
Mild 4/17 (23.5) –
Numbness (%) 8/28 (28.6)
Very severe 0/8 (0.0) Severe 0/9 (0.0)
Severe 1/8 (12.5) Quite a bit 2/9 (22.2)
Moderate 3/8 (37.5) Moderately 0/9 (0.0)
Mild 0/8 (0.0) A little bit 3/9 (33.3)
Very mild 4/8 (50.0) Not at all 4/9 (44.4)
Burning (%) 4/29 (13.8)
Severe 2/4 (50.0) Severe 1/5 (20.0)
Quite a bit 0/4 (0.0) Quite a bit 1/5 (20.0)
Moderate 0/4 (0.0) Moderately 0/5 (0.0)
A little bit 2/4 (50.0) A little bit 1/5 (20.0)
– Not at all 2/5 (40.0)
Difficulty in eating (%) 3/29 (10.3)
Severe 1/3 (33.3) Severe 1/4 (25.0)
Quite a bit 0/3 (0.0) Quite a bit 1/4 (25.0)
Moderate 1/3 (33.3) Moderately 0/4 (0.0)
A little bit 1/3 (33.3) A little bit 0/4 (0.0)
– Not at all 2/4 (50.0)
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21]. The HADS has come under increasing criticism for an
unstable structure that affects interpretability [22]. The deci-
sion to score anxiety and depression separately and categori-
cally was taken before these problems became clear, but made
patient distress hard to interpret. Not all patients completed
every item of the SF-12, which means for 22 patients after
MVD and seven patients after PSR, the SF-12 PCS and
MCS could not be calculated.
Other studies have also compared MVD and PSR, but
comparison with these is difficult to make due to their focus
on pain relief with or without presence of complications
[23–29]. Some studies found that postoperative complications
are more frequent after PSR than MVD, but others found that
the destructive procedure yields similar pain outcomes and
equivocal postoperative complications. Our results suggest
that patients after PSR are more anxious and have more fre-
quent postoperative complications, which have a greater se-
verity and impact on quality of life than MVD. The high
incidence of complications and numbness in this cohort is
consistent with previous reports of PSR [30]. As demonstrated
by patient responses, postoperative complications such as
numbness and burning can seriously affect quality of life,
and this is also reported after stereotactic radiosurgery (SRS)
[31]. Though these complications are well reported after de-
structive procedures, their presence and frequency after MVD
in our cohort was surprising. It was demonstrated that 14.6%
of patients undergoing MVD may develop numbness, which
is milder than after PSR, but can impact on quality of life.
Previous studies have shown neurosensory disturbance after
MVD, including numbness and change of taste [20, 21]. Only
one study in a cohort of patients used the Japanese version of
the SF-36 to assess quality of life after MVD [32]. In this
study, the individual norm-based items: physical role, emo-
tional role and social functioning were significantly lower
than the Japanese population 2 years after MVD, similar to
our comparison with the UK population sample. The only
other two studies assessing quality of life after surgery for
TN reported individual norm-based items of the SF-36 after
SRS. Azar and colleagues [33] found improved SF-36 scores
after SRS, with a mean follow-up of 54 months. Pan and
colleagues [34] found higher scores for individual items of
the SF-36 to be associated with lower pain severity, but did
not report on other complications. Comparison to these studies
is difficult, because of their use of individual items of the SF-
36, rather than calculation of PCS and MCS.
Posterior fossa procedures aim to provide immediate pain
relief for TN. MVD is considered the procedure of choice for
classic TN with NVC, but in patients without NVC, with TN
relapsing after MVD or in patients with a vascular anatomy
that prohibits safe decompression, destructive procedures
such as PSR have been considered a safe and effective alter-
native [30]. Although PSR has largely been discontinued in
routine clinical practice, internal neurolysis is now advocated
in those with no NVC but, as with PSR, the incidence of
numbness after internal neurolysis is high [4]. Neurosensory
disturbance of the trigeminal nerve results in poorer health-
related quality of life [35], as found in our study. There have
been no head-to-head comparisons of PSR against internal
neurolysis, but as they are both destructive procedures, sur-
geons must warn patients of the increased risk of complica-
tions, such as numbness, and their impact on anxiety and
wellbeing to ensure informed consent has been obtained.
The difference between SF-12 scores of patients and English
norms from 2012 is concerning. This may be due to postop-
erative complications and recurrence of pain, but may also be
due to fear of the return of pain, which was not assessed in this
study. In TN, there is risk of development of depressive, anx-
iety or sleep disorders [1], which also reduces quality of life
compared to the general population, and there is no evidence
to suggest that posterior fossa surgery alleviates these.
Regardless of the reasons for poorer quality of life in these
patients, these results suggest unmet needs after surgery, and
in this respect and as previously suggested, that the current
management of TN is suboptimal [36]. Future studies should
seek to determine whether posterior fossa surgery reduces the
incidence of anxiety, depression and fear of recurrence in TN
more effectively than other modalities, such as medications
and Gasserian ganglion surgery. In this cohort, though the
patients’ responses revealed PSR to yield more common and
severe complications that impact quality of life, this was not
reflected by the SF-12. This may be because the SF-12 pro-
vides a generalised measure of the physical and mental dimen-
sions of quality of life, and is not sensitive to the impact of
these postoperative complications after surgery for TN.
Therefore, the next step is to determine from patients them-
selveswhat outcomes they consider important, often divergent
from those routinely assessed, and to estimate minimally im-
portant clinical differences, as has been done for SRS patients
[37, 38]. A recent review identified over 116 quality of life
scales that were categorised into 32 health domains [39].
Ideally a quality of life scale not only represents patients’
priorities but can also be translated into quality-adjusted life
years, which in turn, can be represented in economic terms to
guide treatment choices [40]. As TN is managed by a wide
variety of medical and surgical interventions, arriving at a
consensus for what constitutes the best quality of service
would be of considerable value, as has been done for head-
aches [41].
Conclusions
In conclusion, PSR was associated with a higher risk of post-
operative complications than MVD, which was associated
with anxiety and impacted patients’ rated quality of life, al-
though this was not detected by the SF-12. The quality of life
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of postoperative patients with TN is lower than that of the age-
matched English population, regardless of the surgical proce-
dure, suggesting that this disorder should be regarded as a
long-term condition. Patient-centred outcomes and their as-
sessment in TN remains an under-researched area, but one
of considerable clinical and economic importance.
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Comments
Patient reported outcome measures (PROM) provide a more holistic
assessment of the impact of trigeminal neuralgia therapy than merely
relying on the degree of pain relief. This is especially germane when
we have a number of therapies that can be offered to patients. The present
article reports on reduced quality of life measures undergoing otherwise
successful MVD surgery for trigeminal neuralgia and following open
partial sensory rhizotomy. A comparison with PROMs for patients with
medical treatment only, percutaneous rhizolysis, and radiosurgical thera-
py could provide us with a more nuanced and rational basis for offering
the appropriate therapeutic modality. This may well depend on patient
variables such as age and comorbidities. Furthermore, the duration and
characteristics of the symptomatology may well impact the patient out-
comemeasures for the different treatment modalities.This article provides
the incentive for similar comparative studies to our other treatment mo-
dalities in trigeminal neuralgia.
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